Wednesday, October 14, 2026

Cambridge Bancorp And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 25, 2020

Cambridge Bancorp And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Cambridge Bancorp

48.1% sales growth and 8.19% return on equity

Cambridge Bancorp operates as the bank holding company for Cambridge Trust Company that provides commercial and consumer banking, and investment management and trust services.

Cambridge Bancorp's sales growth this year is expected to be 38.8% and 8.7% for next year.

Year-on-year quarterly revenue growth grew by 50.1%, now sitting on 127.65M for the twelve trailing months.

Cambridge Bancorp's sales growth for the next quarter is 48.1%. The company's growth estimates for the current quarter and the next is 21.5% and 26.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.19%.

Cambridge Bancorp's Stock Yearly Top and Bottom Value

Cambridge Bancorp's stock is valued at $70.67 at 22:22 EST, way under its 52-week high of $81.02 and way above its 52-week low of $44.20.

Cambridge Bancorp's Moving Average

Cambridge Bancorp's worth is above its 50-day moving average of $68.20 and way above its 200-day moving average of $58.75.

2. Hasbro, Inc.

5.9% sales growth and 16.55% return on equity

Hasbro, Inc., together with its subsidiaries, operates as a play and entertainment company.

Hasbro, Inc.'s sales growth this year is anticipated to be 15% and 11.8% for next year.

Year-on-year quarterly revenue growth grew by 12.8%, now sitting on 5.17B for the twelve trailing months.

Hasbro, Inc.'s sales growth for the next quarter is 5.9%. The company's growth estimates for the present quarter and the next is a negative 8.1% and 36.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.55%.

Hasbro, Inc.'s Stock Yearly Top and Bottom Value

Hasbro, Inc.'s stock is valued at $92.38 at 22:22 EST, way below its 52-week high of $109.50 and way above its 52-week low of $41.33.

Hasbro, Inc.'s Moving Average

Hasbro, Inc.'s value is higher than its 50-day moving average of $90.19 and way above its 200-day moving average of $81.68.

3. Restoration Hardware Holdings Inc.

33.9% sales growth and 179.8% return on equity

RH, together with its subsidiaries, operates as a retailer in the home furnishings.

Restoration Hardware Holdings Inc.'s sales growth this year is expected to be 7% and 10.8% for next year.

Year-on-year quarterly revenue growth grew by 24.6%, now sitting on 2.7B for the twelve trailing months.

Restoration Hardware Holdings Inc.'s sales growth for the next quarter is 33.9%. The company's growth estimates for the current quarter and the next is 28.2% and 136.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 179.8%.

Restoration Hardware Holdings Inc.'s Stock Yearly Top and Bottom Value

Restoration Hardware Holdings Inc.'s stock is valued at $458.29 at 22:22 EST, below its 52-week high of $494.40 and way above its 52-week low of $73.14.

Restoration Hardware Holdings Inc.'s Moving Average

Restoration Hardware Holdings Inc.'s worth is above its 50-day moving average of $426.73 and way above its 200-day moving average of $342.02.

4. Tempur Sealy International, Inc.

8.5% sales growth and 63.13% return on equity

Tempur Sealy International, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes bedding products in the United States, Canada, and internationally.

Tempur Sealy International, Inc.'s sales growth this year is expected to be 16.1% and 8.3% for next year.

Year-on-year quarterly revenue growth grew by 37.9%, now sitting on 3.49B for the twelve trailing months.

Tempur Sealy International, Inc.'s sales growth for the next quarter is 8.5%. The company's growth estimates for the ongoing quarter and the next is 50% and 21.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 63.13%.

Tempur Sealy International, Inc.'s Stock Yearly Top and Bottom Value

Tempur Sealy International, Inc.'s stock is valued at $27.30 at 22:22 EST, under its 52-week high of $28.06 and way above its 52-week low of $5.50.

Tempur Sealy International, Inc.'s Moving Average

Tempur Sealy International, Inc.'s value is higher than its 50-day moving average of $24.83 and way higher than its 200-day moving average of $21.59.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com